学会家庭计划委员会声明:癌症患者及癌症幸存者的避孕考虑第一部分——临床照护关键考虑(与妇科肿瘤学会联合发布)
随着癌症诊断和幸存者数量增加,越来越多受癌症影响者需要高质量避孕咨询。该声明指出,癌症患者及幸存者性活动、生育意愿和避孕偏好个体化;临床医生应提供以人为中心的避孕照护,支持自主决策,结合癌症特异性考虑。癌症治疗期间通常建议预防妊娠,但妊娠可能发生在治疗前或治疗中,需以人为中心咨询。无检测能可靠排除癌症幸存者的妊娠可能;临床医生应在癌症治疗前向有妊娠可能者提供避孕讨论。癌症和化疗可导致血管损伤增加静脉血栓栓塞风险、贫血、骨丢失增加骨折风险,应据此咨询避孕选择。癌症患者使用紧急避孕药是安全的。亲密伴侣暴力经历者及其他边缘化人群(包括青少年和年轻成人及性别多元个体)有独特需求。应优先保障癌症患者及幸存者获得全谱系避孕方法。本文为三部分系列第一部分,更新学会家庭计划2012年癌症与避孕临床指南。
要点
- 癌症治疗期间通常建议预防妊娠,但妊娠可能发生在治疗前或治疗中,需以人为中心咨询。
- 无检测能可靠排除癌症幸存者的妊娠可能;应在癌症治疗前向有妊娠可能者提供避孕讨论。
- 癌症和化疗可致血管损伤增加静脉血栓栓塞风险、贫血、骨丢失增加骨折风险,应据此咨询避孕选择。
- 癌症患者使用紧急避孕药是安全的。
- 应优先保障癌症患者及幸存者获得全谱系避孕方法,并关注亲密伴侣暴力经历者、青少年和年轻成人及性别多元个体的独特需求。
适用人群与场景
- 癌症患者及癌症幸存者,包括有妊娠可能者。
- 需关注亲密伴侣暴力经历者及其他边缘化人群,包括青少年和年轻成人及性别多元个体。
处置流程与药物剂量
- 临床医生应提供以人为中心的避孕照护,支持个体自主决策,并 tailored 于个体表达的偏好和价值观,包含癌症特异性考虑。
- 癌症治疗期间通常建议预防妊娠;妊娠可能发生在治疗前或治疗中,需以人为中心咨询。
- 无检测能可靠排除癌症幸存者的妊娠可能;临床医生应在癌症治疗前向有妊娠可能者提供避孕讨论。
- 临床医生应咨询癌症和化疗可能导致的常见风险和并发症对避孕选择的影响:血管损伤增加静脉血栓栓塞风险、贫血、骨丢失增加骨折风险。
- 临床医生应告知癌症患者使用紧急避孕药是安全的。
- 应优先保障癌症患者及幸存者获得全谱系避孕方法,适应个体偏好和健康状况。
研究设计与关键结果
- 该声明为学会家庭计划委员会声明,与妇科肿瘤学会联合发布,更新2012年癌症与避孕临床指南,为三部分系列的第一部分。
证据类型、等级与局限
- 证据类型:学会家庭计划委员会声明(指南/共识)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 临床医生应在癌症治疗前主动向有妊娠可能者提供避孕讨论,因无检测能可靠排除妊娠可能。
- 临床医生应告知癌症患者紧急避孕药是安全的。
- 临床医生应优先保障癌症患者及幸存者获得全谱系避孕方法,并关注亲密伴侣暴力经历者、青少年和年轻成人及性别多元个体的独特需求。
指南或共识出处
- Society of Family Planning Committee Statement: Contraceptive considerations for individuals with cancer and cancer survivors part 1 - Key considerations for clinical care Joint with the Society of Gynecologic Oncology(学会家庭计划委员会声明:癌症患者及癌症幸存者的避孕考虑第一部分——临床照护关键考虑,与妇科肿瘤学会联合发布)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
With increasing trends in both cancer diagnosis and survivorship, a growing number of individuals impacted by cancer need high-quality contraceptive counseling. Individuals with cancer and cancer survivors have individualized needs with respect to sexual activity, fertility desires, and contraceptive preferences. Clinicians should provide person-centered contraceptive care that supports individual autonomy in decision-making, is tailored to the individual's expressed preferences and values, and includes cancer-specific considerations. While pregnancy prevention is generally recommended during cancer treatment, pregnancy may occur before or during treatment and require person-centered counseling. No test reliably rules out pregnancy potential in cancer survivors; clinicians should offer to discuss contraception with individuals who are pregnancy-capable before cancer treatment. Clinicians should counsel individuals about common risks and complications that may impact contraceptive choice, as cancer and chemotherapy can cause (1) vascular injury, which can increase the risk of venous thromboembolism, (2) anemia, and (3) bone loss increasing the risk of fractures. Clinicians should counsel individuals with cancer that it is safe for them to use emergency contraception. Clinicians should be aware that individuals experiencing intimate partner violence and other marginalized populations, including adolescents and young adults and gender-diverse individuals, have unique needs requiring a person-centered approach to contraceptive care complicated by cancer. Access to the full spectrum of contraceptive methods should be prioritized for individuals with cancer and cancer survivors, accommodating individual preferences and health status. This document is part 1 of a three-part series that updates the Society of Family Planning's 2012 Cancer and contraception clinical guidance. Its companion documents, Society of Family Planning Clinical Recommendation: Contraceptive considerations for individuals with cancer and cancer survivors part 2 - Breast, ovarian, uterine, and cervical cancer and Society of Family Planning Clinical Recommendation: Contraceptive considerations for individuals with cancer and cancer survivors part 3 - Skin, blood, gastrointestinal, liver, lung, central nervous system, and other cancers, build upon this document and focus on actionable, clinical recommendations.
参考来源
- Batur P, Brant A, McCourt C, et al. Society of Family Planning Committee Statement: Contraceptive considerations for individuals with cancer and cancer survivors part 1 - Key considerations for clinical care Joint with the Society of Gynecologic Oncology. Contraception. 2025. PMID: 40210504. doi:10.1016/j.contraception.2025.110870
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。